MetaVia
MTVA | NASDAQ
$1.21
-$0.09 (-6.92%)
At close: Nov 16, 2026, 4:00 PM ET
$1.29
+$0.08 (+6.61%)
After-hours:
Nov 16, 2026, 7:48 PM ET
MetaVia Company Profile
Company profile explainedCompany Profile
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Key Executives
| Name | Position |
|---|---|
| Hyung-Heon Kim | Chief Executive Officer, President & Director |
| Marshall H. Woodworth | Chief Financial Officer |
| Mi-Kyung Kim | Chief Scientific Officer |
| Michael C. Pine | Senior Vice President of Business Development Advisor |
| Robert Homolka | Senior Vice President of Clinical Operations |
| W. Christopher Fang | Consulting Chief Medical Officer & Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 8-K | Current Report |
| May 27, 2026 | 8-K | Current Report |
| May 18, 2026 | 8-K | Current Report |
| May 15, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| May 11, 2026 | 8-K | Current Report |
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEF 14A | Filing |
| Apr 15, 2026 | PRE 14A | Filing |
MetaVia
| Country | United States |
| IPO Date | Aug 5, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Hyung Heon Kim |
Contact Details
545 Concord Avenue Cambridge,
Massachusetts 02138 United States
Stock Details
| Ticker Symbol | MTVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638287 |
| CUSIP Number | 64132R503 |
| ISIN Number | US64132R5037 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove MTVA